Gliptin Dosage/Direction for Use

100 mg once daily as monotherapy or as combination therapy with metformin, a sulfonylurea, insulin (with or without metformin), a PPARγ agonist (e.g., thiazolidinediones), metformin plus a sulfonylurea, or metformin plus a PPARγ agonist. Sitagliptin can be taken with or without food.
When Sitagliptin is used in combination with a sulfonylurea or with insulin, a lower dose of sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea-or insulin-induced hypoglycemia.
Renal impairment: eGFR ≥60 mL/minute/1.73 m² to <90 mL/minute/1.73 m²: No dosage adjustment necessary.
eGFR ≥45 mL/minute/1.73 m² to <60 mL/minute/1.73 m²: No dosage adjustment necessary.
eGFR ≥30 mL/minute/1.73 m² to <45 mL/minute/1.73 m²: 50 mg once daily.
eGFR ≥15 mL/minute/1.73 m² to <30 mL/minute/1.73 m² or ESRD (eGFR <15 mL/minute/1.73 m²) requiring hemodialysis or peritoneal dialysis: 25 mg once daily and may be administered without regard to the timing of dialysis.
Hepatic impairment: Mild to moderate impairment (Child-Pugh classes A and B): No dosage adjustment.
Severe impairment (Child-Pugh class C): No dosage adjustment.